Mohammad Mousa, MD
Endocrinology, Diabetes & Metabolism · Monroe, LANPI 1841383221
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.8% of the total across 175 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $730, 2.3 times the $316 reported in 2019. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in LA, where the typical reported total is $3,044.
Across 175 payments — averaging $17.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$649
- Corcept Therapeutics$413
- Acadia Pharmaceuticals Inc$325
- Medtronic$188
- Amgen$185
- AstraZeneca$173
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,91696%
- Education$1284%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 47 | $649 |
| Corcept Therapeutics | 19 | $413 |
| Acadia Pharmaceuticals Inc | 24 | $325 |
| Medtronic(2 entities) | 6 | $188 |
| Amgen(2 entities) | 9 | $185 |
| AstraZeneca | 12 | $173 |
| Lilly USA, LLC | 8 | $154 |
| Xeris Pharmaceuticals, Inc. | 5 | $89 |
| Insulet Corporation | 5 | $83 |
| IBSA Pharma Inc. | 4 | $82 |
| Boehringer Ingelheim | 5 | $74 |
| BETA Bionics, Inc. | 2 | $67 |
| Abbott | 3 | $53 |
| Dexcom, Inc. | 3 | $51 |
| Neurocrine Biosciences, Inc. | 2 | $50 |
| AbbVie | 2 | $45 |
| Evoke Pharma, Inc. | 2 | $42 |
| Novartis | 2 | $33 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Kyowa Kirin, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $23 |
| Novo Nordisk | 1 | $22 |
| Soleno Therapeutics, Inc. | 1 | $22 |
| Sequel Med Tech, LLC | 1 | $18 |
| Acella Pharmaceuticals, LLC | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $16 |
| Nevro Corp. | 1 | $16 |
| Ascendis Pharma Endocrinology Inc | 1 | $16 |
| Urovant Sciences Inc | 1 | $13 |
How this compares
$3,044 in reported general payments places this provider in the 50th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 523 | $602,714 |
| KorlymMifepristone | 14 | $410,271 |
| IngrezzaValbenazine Tosylate | 106 | $388,695 |
| OzempicSemaglutide | 368 | $373,913 |
| EliquisApixaban | 710 | $214,458 |
| NuedextaDextromethorphan Hbr/Quinidine | 248 | $189,189 |
| JardianceEmpagliflozin | 396 | $177,593 |
| NuplazidPimavanserin Tartrate | 52 | $128,767 |
| TrulicityDulaglutide | 82 | $87,048 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 117 | $85,583 |
| Humira PenAdalimumab | 11 | $82,717 |
| TradjentaLinagliptin | 283 | $75,178 |
| EntrestoSacubitril/Valsartan | 175 | $59,972 |
| FarxigaDapagliflozin Propanediol | 109 | $50,748 |
| XifaxanRifaximin | 31 | $47,877 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $154 | $689,762605 claims |
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $22 | $455,592529 claims |
| Corcept TherapeuticsKorlym | $413 | $410,27114 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $50 | $388,695106 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Synjardy | $74 | $290,059734 claims |
| Acadia Pharmaceuticals IncNuplazid | $325 | $128,76752 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $173 | $62,532126 claims |
| NovartisEntresto | $33 | $59,972175 claims |
| AbbVieLinzess | $45 | $42,80775 claims |
| BayerKerendia | $649 | $35,72049 claims |
| Astellas Pharma US IncMyrbetriq | $16 | $16,82873 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $24 | $10,47743 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Monroe
- Resham PoudelMonroe$2K
- Timothy GilbertBaton Rouge$985K
- Vivian FonsecaNew Orleans$658K
- Abdul KhanHammond$587K
- Marideli ScanlanMarrero$444K
- Justin FontenotLafayette$397K
- Ileana TandronSlidell$205K
- Lane FreyThibodaux$202K
- Laura Kimball RavariBossier City$165K
- Lawrence BlondeNew Orleans$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.